ProfRadboud University Medical CenterNijmegen, Gelderland, Netherlands
I do not have any relevant financial / non-financial relationships with any proprietary interests.
870 - Olorofim for the treatment of invasive mould infections in patients with limited or no treatment options: Comparison of interim results from a Phase 2B open-label study with outcomes in historical control populations (NCT03583164, FORMULA-OLS, Study 32)
Friday, October 21, 202211:00 AM - 11:15 AM US ET